Very good. Most of the money goes directly to the science. And let's move on with the short business update.
So as mentioned, we have a completed Phase 1 program. Just a short recap of what the Phase 1 program told us and what will be the next steps.
So the Phase 1a clinical trial that we completed a couple of years ago was a single ascending dose study in healthy individuals. And we also had elderly individuals there to take cerebrospinal fluid samples to show the brain penetration profile of HER-096.
And the main findings were very good safety and tolerability profile of the single dose.
We demonstrated efficient brain penetration in elderly, healthy individuals. And the brain penetration was very much aligned with the preclinical findings.
We had reported earlier. And we also have very favorable pharmacokinetic profile considering the administration. And now we completed a Phase 1 clinical trial where we first had a couple of additional elderly individuals for single administration to complete some of the pharmacokinetic work. Then we had Parkinson's patients in two cohorts with two dose levels, 200 mg and 300 mg doses, and placebo patients as well. And these patients received HER-096 or placebo treatment for four weeks.
Two administrations per week. The main findings continued to show a good safety and tolerability profile in Parkinson's patients. We established the pharmacokinetics in the cerebrospinal fluid in these patients.
And, of course, a biological response was observed in biomarker analysis, which I will provide further insight into here, along with a recap of the webinar we held in early January.
About the safety profile. Here is a very high-level summary of the systemic safety findings from patients or healthy individuals receiving HER-096 dosing. So, on the systemic level, we didn't see any treatment-emergent adverse events, no serious adverse events, and no dose-limiting toxicities. And we didn't reach, obviously, the maximum tolerated dose.
And this was very much aligned with the preclinical studies.
The main incidence that we saw was related to the injection site.
It was mild, transient, and self-resolving, exactly aligned with preclinical findings. And this is of course very good.
And then the second part of the results is obviously the presence of HER-096 in the cerebrospinal fluid.
And this data summarizes what we learned from the Parkinson's patients in the Phase 1b with 200 mg dose. We ended up close to 100 nanograms per mL; with the 300mg dose, close to 150 nanograms per mL. And again, this is very much aligned with the preclinical data.
And these levels are comparable to those levels that we have seen in preclinical settings to provide the maximum efficacy in those models. So we believe that 300mg dose will be a very good dose for going forward with Phase 2. And this is also supported by the biomarker data.
And just a short recap of what did we see in the biomarker data.
And just a reminder that we analyzed different sample types with different technologies. But the main comparison was the change that we observed when we compared the before dosing sample of the last dose to the before dosing sample of the first dose. So a cumulative effect of four weeks exposure to HER-096.
So we had samples from CSF.
So demonstrating what happens in the CNS. And there we showed an effect on proteostasis and oxidative stress and inflammation. So, it is closely related to the Unfolded Protein Response pathway and mitochondrial function. Then we had samples that are called neuronal-enriched extracellular vesicles. So particles that come from the central nervous system.
The sample is taken from the blood. So we can't say for sure that all the signals come from the CNS. But maybe the majority of that. And again, we see changes in mitochondrial functions and also inflammation, very much aligned with the mechanism of action. And then from plasma and blood. We also saw changes in proteostasis and in mitochondrial functions. So these are multiple layers of data showing very concordant results across different sample types. Different locations where we derive the samples show that there is a very clear biological response.
And this is a true response in Parkinson's patients.
And the response is aligned with the mechanism of action.
So if I summarize in one slide what we see.
At baseline, Parkinson's patients have a chronically activated unfolded protein response pathway. So there is. Dysfunction of proteostasis. There is also a lower activity of mitochondrial function.
So Mitochondria are the energy factories of the cell. And there is elevated oxidative stress. So overall, the stress level is high, and cellular viability and function are low. After HER-096 dosing, we see elevation of proteostasis activity. We see elevation of mitochondrial function. We see a decrease in oxidative stress. So we have decreased the stress and increased the viability functionality.
And then of course the very good question is, as this is the data from the first month, what happens after a longer treatment period? And we of course believe and hope that it will result in symptomatic improvement and disease modification. And this is, of course, the purpose of running the Phase 2 trial to demonstrate this in Parkinson's patients, which would then allow going forward with the commercialization path.
So if I summarize where we are with HER-096, we believe that we have reduced development risk based on the very successful Phase 1 trial. We have established. Very nice safety profile, confirmed brain penetration. We have biomarker confirmed biological activity.
So we believe that we have much reduced translational risk. We are ready for Phase 2. So we are planning a signal seeking proof-of-concept efficacy trial in approximately 100 early-stage Parkinson's patients. It will be a multicenter European study if we run that ourselves, and we are currently nearing the confirmation of the study design; it's not completely ready yet. But we, of course, will inform the market when we are ready to do so.
HER-096 is very much a differentiated asset.
So it's a first-in-class peptide that we are focusing on. The Unfolded Protein Response pathway is being addressed. We are doing so as the only company in clinical development. With that, we target the core drivers of Parkinson's pathology. And we really have designed from the beginning the asset to really modify or stop the progression of the disease.
And of course, what we are currently doing, we are looking at the different routes and options, how we can execute the Phase 2. And we are in discussions with strategic partners. We are in discussions with investors. We also confirmed the 8 million Horizon Europe grant that will support the conduct of the study. And we are also looking at different non-dilutive opportunities.
There might also be other non-dilutive opportunities, but of course, we will inform the market as soon as we have anything material on this resourcing of the Phase 2 efficacy trial.
I want to highlight the strong external validation and financial support that we have for HER-096.
HER-096, Parkinson's UK, the Michael J. Fox Foundation financed the majority of the Phase 1 clinical trial with almost 4 million research financing. And we obviously continue to discuss with them how they could support the conduct of the Phase 2.
We have also had very strong support from the European Union.
We completed a biomarker development programme worth 2.5 million euros, and that was completed approximately a year ago. We have secured a 15 million investment commitment from EIC Fund, from which we have now utilised 4.2 million. So, over 10 million still remains in that commitment. And we just announced an €8 million EU grant to support the Phase 2 trial. So we have been quite successful in achieving this validation.
And I have to highlight that all of these financiers and the financing are really competitive vehicles and opportunities. So we have been really happy that our science and the commercial potential have been evaluated to be really strong among these organizations. So as a summary, we believe that HER-096 is a potentially game-changing therapy that could become the first disease-modifying treatment for Parkinson's disease.
We have a huge market opportunity. We are backed by strong research and robust external validation. And one thing that I didn't address yet is that the broad functionality of HER-096 in the basic biology of aging cells, improving the tolerance against different stress factors, may open wide therapeutic opportunities in other neurodegenerative disorders or even beyond CNS indications.
By these words, I think we will end the business update and we are ready to start the Q&A session.